191469-29-1 Usage
Uses
Used in Ophthalmology:
AGN 195183 is used as a therapeutic agent for the treatment of glaucoma and ocular hypertension. It is effective in lowering intraocular pressure, which is crucial for preventing optic nerve damage and vision loss associated with these conditions.
Used in Glaucoma Management:
In the field of glaucoma management, AGN 195183 is used as a medication to reduce intraocular pressure. Its once-daily administration makes it a convenient and well-tolerated treatment option for patients, helping to manage the condition and prevent further progression.
Used in Ocular Hypertension Treatment:
AGN 195183 is also used in the treatment of ocular hypertension, where it serves to decrease the elevated intraocular pressure. This helps in reducing the risk of developing glaucoma and associated vision problems.
Used in Preventing Optic Nerve Damage:
As a medication that lowers intraocular pressure, AGN 195183 is used to prevent optic nerve damage, which is a common consequence of untreated or poorly managed glaucoma and ocular hypertension.
Used in Vision Preservation:
By effectively managing intraocular pressure, AGN 195183 plays a vital role in preserving vision for patients suffering from glaucoma and ocular hypertension, thus improving their quality of life and reducing the risk of vision loss.
Check Digit Verification of cas no
The CAS Registry Mumber 191469-29-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,9,1,4,6 and 9 respectively; the second part has 2 digits, 2 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 191469-29:
(8*1)+(7*9)+(6*1)+(5*4)+(4*6)+(3*9)+(2*2)+(1*9)=161
161 % 10 = 1
So 191469-29-1 is a valid CAS Registry Number.
191469-29-1Relevant academic research and scientific papers
Beard, Richard L.,Duong, Tien T.,Teng, Min,Klein, Elliott S.,Standevan, Andrew M.,Chandraratna, Roshantha A.S.
, p. 3145 - 3148 (2002)
Retinoids are analogues of all-trans-retinoic acid, a powerful hormone that mediates many fundamental biological processes. Cancer and other serious hyperproliferative diseases are attractive therapeutic targets for retinoids, but the therapeutic use of retinoids is limited due to severe toxicity. We report here the design of retinoid receptor-α specific ligands with growth inhibitory activity in breast cancer cell lines, and which do not cause the cutaneous toxicity associated with the currently available nonselective retinoid agonists.
